Princeton: Bristol Myers Squibb has announced the Phase 3 ODYSSEY-HCM trial evaluating Camzyos (mavacamten) for the treatment ...

A one-year prospective study found no correlation between atherosclerosis and extremely high cholesterol levels in 100 ...

People with type O blood enjoy a slightly lower risk of heart disease and blood clotting, but they may be more susceptible to hemorrhaging or bleeding disorders. This may be especially true after ...

An international team of researchers has discovered a natural mechanism that protects the heart from heart failure with preserved ejection fraction (HFpEF), a serious condition in need of effective ...

The New Jersey-based company's shares fell 1.6% in extended trading. The drug, mavacamten, was tested in adult patients with ...

Bristol Myers Squibb’s examination into whether its heart med Camzyos can spark improvements in patients with non-obstructive ...

Camzyos’ failure in a form of hypertrophic cardiomyopathy dampened its commercial outlook and spurred debate as to whether ...

According to analysts at BMO Capital Markets, non-obstructive hypertrophic cardiomyopathy would have meant a $1.3 billion ...

People with a certain heart valve abnormality are at increased risk of severe heart rhythm disorders, even after successful valve surgery.

The result is a major disappointment for BMS as it effectively cuts the potential market for Camzyos in half. Sales of the ...

Ferhaan Ahmad, M.D., Ph.D., FAHA, is the new editor-in-chief of Circulation: Genomic and Precision Medicine, a peer-reviewed scientific journal published by the American Heart Association, effective ...